Shares in British biopharmaceutical firm Mereo Biopharma ($MREO) saw a wipeout of over 90% on Monday after two of its ...

Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) tumbled 43.7% to $19.26 in pre-market trading after the company and its partner ...

Investing.com -- Mereo BioPharma Group plc (NASDAQ:MREO) stock plunged 90.3% on Monday after the company announced that its Phase 3 clinical trials for setrusumab in Osteogenesis Imperfecta failed to ...

The Dow Jones Industrial Average and other major indexes fell Monday afternoon as investors sold holdings in this ...

Cytokinetics is a late-stage biopharmaceutical company targeting muscle function. Its stock has gained almost 30% this year, ...

ArriVent BioPharma is rated a Strong Buy, driven by Firmonertinib’s clinical progress and de-risking. Click here to read my ...

Ultragenyx Pharmaceutical and Mereo BioPharma said their two Phase 3 trials for setrusumab to treat rare bone disorder osteogenesis imperfecta, didn't meet their main goal of reducing fracture rates.

December 22, 2025 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma"),understands that Quantum ...

The biotechnology firm, which develops small-molecule drugs for oncological and inflammatory diseases, revealed plans for a 1-for-3,000 reverse split of its ordinary shares. The move comes after ...

Xeris Biopharma’s Q3 gross margin improved to 85%. It has raised 2025 guidance to $285–290M, but shares fell 30%. See more on ...

On December 16, Julian Emanuel, Senior Managing Director at Evercore ISI, shared his outlook on the equity market and the ...

The BioWorld Biopharmaceutical Index extended its autumn rally after a more modest September, finishing November up 23.41% for the year. The gain lagged the Nasdaq Biotechnology Index, which surged 34 ...